Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2026-06-05 18:16:16 ET · period of report 2026-06-04 · accession 0001916987-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-05 18:16 | 2026-06-04 | XERS | Brady James Aloysius | Dir | A - Grant | $0.00 | +24.2K | 113.4K | +27% | $0 |
| D | 2026-06-05 18:16 | 2026-06-04 | XERS | Brady James Aloysius | Dir | A - Grant | $6.15 | +33.0K | 33.0K | New | +$202.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-04 | A | A | 24,193 | $0.00 | 113,359 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-06-04 | A | A | 32,996 | $6.15 | 32,996 | D | $6.15 · — to 2036-06-04 | 32,996 Common Stock | (F2) These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |